Cyclosporine A sterically inhibits statin transport by solute carrier OATP1B1
Journal of Biological Chemistry · 2025-05 · 301 (5) · 108484
DOI: 10.1016/j.jbc.2025.108484 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2025-05. Verfasst von Min Woo Sung und 11 weiteren Autor:innen. Beteiligte Einrichtung: Discovery Sciences, Discovery & Early Development, Pfizer Inc, Groton, Connecticut, USA. Hauptthemen laut MEDLINE: Cyclosporine, Liver-Specific Organic Anion Transporter 1, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Atorvastatin. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Members of the Organic Anion Transporter Polypeptides (OATP) are integral membrane proteins responsible for facilitating the transport of organic anions across the cell membrane. OATP1B1 (SLCO1B1), the prototypic OATP family member, is the most abundant uptake transporter in the liver and a key mediator of the hepatic uptake and clearance of numerous endogenous and xenobiotic compounds. It serves as a locus of important drug-drug interactions, such as those between statins and cyclosporine A, and carries the potential to enable liver-targeting therapeutics. In this study, we report cryo-EM structures of OATP1B1 and its complexes with one of its statin substrates, atorvastatin, and an inhibitor, cyclosporine A. This structural analysis has yielded insights into the mechanisms underlying the OATP1B1-mediated transport of statins and the inhibitory effect of cyclosporine A. These findings contribute to a better understanding of the molecular processes involved in drug transport and offer potential avenues for the development of targeted medications for liver-related conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Discovery Sciences, Discovery & Early Development, Pfizer Inc, Groton, Connecticut, USA.
- Linkster Therapeutics AG, Zurich, Switzerland.
- Pharmacokinetics, Dynamics, and Metabolism, Discovery & Early Development, Pfizer Inc, Groton, Connecticut, USA.
- Discovery Sciences, Discovery & Early Development, Pfizer Inc, Groton, Connecticut, USA. Electronic address: shenping.liu@pfizer.com.
- Discovery Sciences, Discovery & Early Development, Pfizer Inc, Groton, Connecticut, USA. Electronic address: seungil.han@pfizer.com.
Zitieren
APA
Sung, M. W., Hu, K., Hurlimann, L. M., Lees, J. A., Fennell, K. F., West, M. A., Costales, C., Rodrigues, A. D., Zimmermann, I., Dawson, R. J. P., Liu, S., & Han, S. (2025). Cyclosporine A sterically inhibits statin transport by solute carrier OATP1B1. Journal of Biological Chemistry, 301(5), 108484. https://doi.org/10.1016/j.jbc.2025.108484
Vancouver
Sung MW, Hu K, Hurlimann LM, Lees JA, Fennell KF, West MA, et al. Cyclosporine A sterically inhibits statin transport by solute carrier OATP1B1. Journal of Biological Chemistry. 2025;301(5):108484. doi:10.1016/j.jbc.2025.108484
BibTeX
@article{Sung2025,
author = {Sung, Min Woo and Hu, Kuan and Hurlimann, Lea M and Lees, Joshua A and Fennell, Kimberly F and West, Mark A and Costales, Chester and Rodrigues, Amilcar David and Zimmermann, Iwan and Dawson, Roger J P and Liu, Shenping and Han, Seungil},
title = {Cyclosporine A sterically inhibits statin transport by solute carrier OATP1B1},
journal = {Journal of Biological Chemistry},
year = {2025},
volume = {301},
number = {5},
pages = {108484},
doi = {10.1016/j.jbc.2025.108484}
}
EUVIMED